Antimitotic drugs in the treatment of cancer

Cancer Chemotherapy and Pharmacology

Volumn 76, Issue 6, 2015, Pages 1101-1112

  Van Vuuren, Rustelle Janse ^a   Visagie, Michelle H ^a   Theron, Anne E ^a   Joubert, Annie M ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

2 Methoxyestradiol; Epothilones; Estrogens; Taxanes; Vinca alkaloids

Indexed keywords

2 METHOXYESTRADIOL; ANTIMITOTIC AGENT; CABAZITAXEL; DRUG ANALOG; EPOTHILONE A; EPOTHILONE B; ESTRADIOL; FULVESTRANT; IXABEPILONE; PACLITAXEL; VINTAFOLIDE; TAXOID; TUMOR MARKER; VINCA ALKALOID;

APOPTOSIS; AUTOPHAGY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL CYCLE; COMPUTER MODEL; DRUG MECHANISM; HUMAN; M PHASE CELL CYCLE CHECKPOINT; MALIGNANT NEOPLASTIC DISEASE; MICROTUBULE; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; CELL PROLIFERATION; CLASSIFICATION; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; NEOPLASMS;

ANTIMITOTIC AGENTS; APOPTOSIS; BIOMARKERS, TUMOR; CELL CYCLE; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; TAXOIDS; VINCA ALKALOIDS;

EID: 84947565813     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-015-2903-8     Document Type: Review

References (107)

1. Siegel RL, Miller KD, Jemal A (2015) Cancer statistics. CA Cancer J Clin 65:5-29
2. GLOBOCAN/World Health Organization (2012) Cancer facts sheets. IARC. http://globocan.iarc.fr/Pages/fact-sheets-cancer.aspx. Accessed 16 May 2014
3. Hanahan D, Ra Weinberg (2011) Hallmarks of cancer: the next generation. Cell 144:646-674
4. Hahn WC, Stewart SA, Brooks MW, York SG, Eaton E, Kurachi A, Beijersbergen RL, Knoll JHM, Meyerson M, Weinberg RA (1999) Inhibition of telomerase limits the growth of human cancer cells. Nat Med 5:1164-1170
5. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP (2009) Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 9:862-873
6. Cuttitta F, Carney DN, Mulshine J, Moody TW, Fedorko J, Fischler A et al (1985) Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature 316:823-825
7. Kim MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang XHF, Norton L, Massagué J (2009) Tumor self-seeding by circulating cancer cells. Cell 139:1315-1326
8. Cairns RA, Harris IS, Mak TW (2011) Regulation of cancer cell metabolism. Nat Rev Cancer 11:85-95
9. Tindle RW (2002) Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer 2:59-64
10. de Visser KE, Eichten A, Coussens LM (2006) Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6:24-37
11. Dougan M, Dranoff G (2012) Immunotherapy of cancer. In: Wang R-F (ed) Innate immune regulation and cancer immunotherapy, 1st edn. Springer, New York, pp 391-414
12. Palucka K, Ueno H, Banchereau J (2011) Recent developments in cancer vaccines. J Immunol 186:1325-1331
13. Brannon-Peppas L, Blanchette JO (2012) Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliver Rev 64:206-212
14. Masawang K, Pedro M, Cidade H, Reis RM, Neves MP, Corrêa AG, Sudprasert W, Bousbaa H, Pinto MM (2014) Evaluation of 2′, 4′-dihydroxy-3, 4, 5-trimethoxychalcone as antimitotic agent that induces mitotic catastrophe in MCF-7 breast cancer cells. Toxicol Lett 229:393-401
15. Mitchison TJ (2012) The proliferation rate paradox in antimitotic chemotherapy. Mol Biol Cell 23:1-6
16. Dumontet C, Jordan MA (2010) Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 9:790-803
17. Kavallaris M (2010) Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 10:194-204
18. Jordan MA, Kamath K (2007) How do microtubule-targeted drugs work? Curr Cancer Drug Targets 7:730-742
19. Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4:253-265
20. Liu Y-M, Chen H-L, Lee H-Y, Liou J-P (2014) Tubulin inhibitors: a patent review. Expert Opin Ther Pat 24:69-88
21. Cruz-Monserrate Z, Mullaney JT, Harran PG, Pettit GR, Hamel E (2003) Dolastatin 15 binds in the vinca domain of tubulin as demonstrated by Hummel-Dreyer chromatography. Eur J Biochem 270:3822-3828
22. Attard G, Greystoke A, Kaye S, De Bono J (2006) Update on tubulin-binding agents. Pathol Biol 54:72-84
23. Altmann K-H (2001) Microtubule-stabilizing agents: a growing class of important anticancer drugs. Curr Opin Chem Biol 5:424-431
24. Kanakkanthara A, Northcote PT, Miller JH (2012) βII-tubulin and βIII-tubulin mediate sensitivity to peloruside A and laulimalide, but not paclitaxel or vinblastine, in human ovarian carcinoma cells. Mol Cancer Ther 11:393-404
25. Gaitanos TN, Buey RM, Díaz F, Northcote PT, Spittle PT, Andreu JM, Miller JH (2004) Peloruside A does not bind to the taxoid site on β-tubulin and retains its activity in multidrug-resistant cell lines. Cancer Res 64:5063-5067
26. Pryor DE, O'Brate A, Blicer G, Díaz JF, Wany Y, Wang Y, Kabaki M, Jung MK, Andreu JM, Ghosh AK, Giannakakou P, Hamel E (2002) The microtubule stabilizing agent laulimalide does not bind in taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity. Biochemistry 41:9109-9115
27. Sánchez-Martínez C, Gelbert LM, Lallena MJ, de Dios A (2015) Cyclin dependent kinase (CDK) inhibitors as anticancer drugs. Bioorg Med Chem Lett 25:3420-3435
28. Berridge MJ (2012) Cell signaling biology. Portland Press Ltd, London
29. Bartkova J, Lukas J, Guldberg P, Alsner J, Kirkin AF, Zeuthen J, Bartek J (1996) The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res 56:5475-5483
30. Takizawa CG, Morgan DO (2000) Control of mitosis by changes in the subcellular location of cyclin-B1-Cdk1 and Cdc25C. Curr Opin Cell Biol 12:658-665
31. Musacchio A, Salmon ED (2007) The spindle-assembly checkpoint in space and time. Nat Rev Mol Cell Biol 8:379-393
32. Giam M, Rancati G (2015) Aneuploidy and chromosomal instability in cancer: a jackpot to chaos. Cell Div 10:3-12
33. Shannon KB, Canman JC, Salmon ED (2002) Mad2 and BubR1 function in a single checkpoint pathway that responds to a loss of tension. Mol Biol Cell 13:3706-3719
34. Sudakin V, Chan GK, Yen TJ (2001) Checkpoint inhibition of the APC/C in HeLa cells is mediated by a complex of BUBR1, BUB3, CDC20, and MAD2. J Cell Biol 154:925-936
35. Weiss E, Winey M (1996) The Saccharomyces cerevisiae spindle pole body duplication gene MPS1 is part of a mitotic checkpoint. J Cell Biol 132:111-123
36. Chen R-H, Shevchenko A, Mann M, Murray A (1998) Spindle checkpoint protein Xmad1 recruits XMad2 to unattached kinetochores. J Cell Biol 143:283-295
37. Sharp-Baker H, Chen R-H (2001) Spindle checkpoint Bub1 is required for kinetochore localization of Mad1, Mad2, Bub3, and CENP-E, independently of its kinase activity. J Cell Biol 153:1239-1250
38. Burke DJ, Stukenberg PT (2008) Linking kinetochore-microtubule binding to the spindle checkpoint. Dev Cell 14:474-479
39. Hagting A, den Elzen N, Vodermaier HC, Waizenegger IC, Peters J-M, Pines J (2002) Human securin proteolysis is controlled by the spindle checkpoint and reveals when the APC/C switches from activation by Cdc20 to Cdh1. J Cell Biol 157:1125-1137
40. Sun Y, Kucej M, Fan H-Y, Yu H, Sun Q-Y, Zou H (2009) Separase is recruited to mitotic chromosomes to dissolve sister chromatid cohesion in a DNA-dependent manner. Cell 137:123-132
41. Elmore S (2007) Apoptosis: a review of programmed cell death. Toxicol Pathol 35(4):495-516
42. Sorrentino G, Comel A, Del Sal G (2015) p53 orchestrates calcium signaling in vivo. Cell Cycle 14:1343-1344
43. Li H, Jia Z, Li G, Zhao X, Sun P, Wang J, Fan Z, Lv G (2015) Neuroprotective effects of exendin-4 in rat model of spinal cord injury via inhibiting mitochondrial apoptotic pathway. Int J Clin Exp Pathol 8:4837-4843
44. Nkandeu DS, Mqoco TV, Visagie MH, Stander BA, Wolmarans E, Cronje MJ, Joubert AM (2013) In vitro changes in mitochondrial potential, aggresome formation and caspase activity by a novel 17-β-estradiol analogue in breast adenocarcinoma cells. Cell Biochem Funct 31:566-574
45. Kelly PS, Strasser A (2011) The role of Bcl-2 and its pro-survival relatives in tumorigenesis and cancer therapy. Cell Death Differ 18:1414-1424
46. Krajewski S, Krajewska M, Shabaik A, Wang H-G, Irie S, Fong L, Reed JC (1994) Immunohistochemical analysis of in vivo patterns of Bcl-X expression. Cancer Res 54:5501-5507
47. Bae IH, Park M-J, Yoon SH, Kang SW, Lee S-S, Choi K-M, Um H-D (2006) Bcl-w promotes gastric cancer cell invasion by inducing matrix metalloproteinase-2 expression via phosphoinositide 3-kinase, Akt, and Sp1. Cancer Res 66:4991-4995
48. Liu W, Bulgaru A, Haigentz M, Stein C, Perez-Soler R, Mani S (2003) The BCL2-family of protein ligands as cancer drugs: the next generation of therapeutics. Curr Med Chem 3:217-223
49. Lamidi OF, Sani M, Lazzari P, Zanda M, Fleming IN (2015) The tubulysin analogue KEMTUB10 induces apoptosis in breast cancer cells via p53, Bim and Bcl-2. J Cancer Res Clin Oncol 141:1575-1583
50. Broadhead ML, Dass CR, Choong PF (2009) Cancer cell apoptotic pathways mediated by PEDF: prospects for therapy. Trends Mol Med 15:461-467
51. Ashkenazi A, Dixit VM (1999) Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 11:255-260
52. McDermott MF (2001) TNF and TNFR biology in health and disease. Cell Mol Biol 47:619-636
53. Ganten T, Haas T, Sykora J, Stahl H, Sprick M, Fas S, Krueger A, Weigand MA, Grosse-Wilde A, Stremmel W, Krammer PH, Walczak H (2004) Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ 11:86-96
54. Jang M-S, Lee S-J, Kang NS, Kim E (2011) Cooperative phosphorylation of FADD by Aur-A and Plk1 in response to taxol triggers both apoptotic and necrotic cell death. Cancer Res 71:7207-7215
55. Amaravadi RK, Lippincott-Schwartz J, Yin X-M, Weiss WA, Takebe N, Timmer W, DiPaola RS, Lotze MT, White E (2011) Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res 17:654-666
56. Veldhoen R, Banman S, Hemmerling D, Odsen R, Simmen T, Simmonds A, Underhill DA, Goping IS (2013) The chemotherapeutic agent paclitaxel inhibits autophagy through two distinct mechanisms that regulate apoptosis. Oncogene 32:736-746
57. Bedard PL, Di Leo A, Piccart-Gebhart MJ (2010) Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer. Nat Rev Clin Oncol 7:22-36
58. Cella D, Peterman A, Hudgens S, Webster K, Socinski MA (2003) Measuring the side effects of taxane therapy in oncology. Cancer 98:822-831
59. Baldo BA, Pham NH (2013) Drugs used for chemotherapy. Drug allergy, 1st edn. Springer, New Yoek, pp 399-418
60. de Hoon JP, Veeck J, Vriens BE, Calon TG, van Engeland M, Tjan-Heijnen VC (2012) Taxane resistance in breast cancer: a closed HER2 circuit? BBA-Rev Cancer 1825:197-206
61. Mita AC, Figlin R, Mita MM (2012) Cabazitaxel: more than a new taxane for metastatic castrate-resistant prostate cancer? Clin Cancer Res 18:6574-6579
62. ®) for the treatment of hormone-refractory metastatic prostate cancer: summary of the scientific assessment of the committee for medicinal products for human use. Oncologist 17:543-549
63. Risinger AL, Mooberry SL (2012) Microtubules as a target in cancer therapy. In: Kavallaris M (ed) Cytoskeleton and Human Disease, 1st edn. Humana Press, New York, pp 203-221
64. Rogalska A, Marczak A, Gajek A, Szwed M, ͆liwińska A, Drzewoski J, Jóźwiak Z (2013) Induction of apoptosis in human ovarian cancer cells by new anticancer compounds, epothilone A and B. Toxicol In Vitro 27:239-249
65. Cortazar P, Justice R, Johnson J, Sridhara R, Keegan P, Pazdur R (2012) US Food and Drug Administration approval overview in metastatic breast cancer. J Clin Oncol 30:1705-1711
66. Shen H, Lee FY, Gan J (2011) Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther 337:423-432
67. Ravelli RB, Gigant B, Curmi PA, Jourdain I, Lachkar S, Sobel A, Knossow M (2004) Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 428:198-202
68. Swami U, Chaudhary I, Ghalib MH, Goel S (2012) Eribulin - a review of preclinical and clinical studies. Crit Rev Oncol Hematol 81:163-184
69. Zheng W, Seletsky B, Palme M, Habgood G, Singer L, Dipietro LV, Chen JJ, Lydon PJ, Quincy DA, Towle MJ, Salvato KA, Wels BF, Kuznetsov G, Aalfs KK, Kishi Y, Lewis MD, LittleWeld BA, Yu MJ (2003) Structure-activity relationships of synthetic halichondrin B analog E7389: in vitro susceptibility to PgP-mediated drug efflux. Proc Am Assoc Cancer Res 7:2751
70. Edelman MJ, Harb WA, Pal SE, Boccia RV, Kraut MJ, Bonomi P, Conley BA, Rogers JS, Messmann RA, Garon EB (2012) Multicenter trial of EC145 in advanced, folate-receptor positive adenocarcinoma of the lung. J Thorac Oncol 7:1618-1621
71. Naumann RW, Coleman RL, Burger RA, Sausville EA, Kutarska E, Ghamande SA, Gabrail NY (2013) PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. J Clin Oncol 31:4400-4406
72. Leamon CP, Vlahov IR, Reddy JA, Vetzel M, Santhapuram HKR, You F, DePasquale SE, Nowara E, Gilbert L, Gersh RH, Teneriello MG, Harb WA, Konstantinopoulos PA, Penson RT, Symanowski JT, Lovejoy CD, Leamon CP, Morgenstern DE, Messmann RA (2014) Folate-vinca alkaloid conjugates for cancer therapy: a structure-activity relationship. Bioconjug Chem 25:560-568
73. Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon CP (2005) Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 338:284-293
74. Leamon CP (2008) Folate-targeted drug strategies for the treatment of cancer. Curr Opin Investig Drugs 9:1277-1286
75. Wan Z, Musa MA, Joseph P, Cooperwood JS (2013) Synthesis and biological activity of 3-N-substituted estrogen derivatives as breast cancer agents. Mini Rev Med Chem 13:1381
76. Filardo EJ, Thomas P (2012) Minireview: G protein-coupled estrogen receptor-1, GPER-1: its mechanism of action and role in female reproductive cancer, renal and vascular physiology. Endocrinology 153:2953-2962
77. Abdulkareem I, Zurmi I (2012) Review of hormonal treatment of breast cancer. Niger J Clin Pract 15:9-14
78. Howarth NM, Purohit A, Reed MJ, Potter BV (1994) Estrone sulfamates: potent inhibitors of estrone sulfatase with therapeutic potential. J Med Chem 37:219-221
79. Pasqualini J, Chetrite G, Blacker C, Feinstein M, Delalonde L, Talbi M, Maloche C (1996) Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre-and postmenopausal breast cancer patients. J Clin Endocrinol Metab 81:1460-1464
80. Pasqualini JR (2004) The selective estrogen enzyme modulators in breast cancer: a review. Biochim Biophys Acta 1654:123-143
81. Henderson BE, Ross R, Bernstein L (1988) Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res 48:246-253
82. Gökmen-Polar Y, Escuin D, Walls CD, Soule SE, Wang Yuefang, Sanders Kerry L, LaVallee Theresa M, Wang M, Guenther BD, Giannakakou P, Sledge GW (2005) β-Tubulin mutations are associated with resistance to 2-methoxyestradiol in MDA-MB-435 cancer cells. Cancer Res 65:9406-9414
83. Stander BA, Joubert F, Tu C, Sippel KH, McKenna R, Joubert AM (2013) Signaling pathways of ESE-16, an antimitotic and anticarbonic anhydrase estradiol analog, in breast cancer cells. PLoS One 8:e53853-e53871
84. Stander A, Joubert F, Joubert A (2011) Docking, synthesis, and in vitro evaluation of antimitotic estrone analogs. Chem Biol Drug Des 77:173-181
85. Stander BA, Joubert F, Tu C, Sippel KH, McKenna R, Joubert AM (2012) In vitro evaluation of ESE-15-ol, an estradiol analogue with nanomolar antimitotic and carbonic anhydrase inhibitory activity. PLoS One 7:e52205
86. Thiry A, Dogne J-M, Masereel B, Supuran CT (2006) Targeting tumor-associated carbonic anhydrase IX in cancer therapy. Trends Pharmacol Sci 27:566-573
87. Shin H-J, Rho SB, Jung DC, Han I-O, Oh E-S, Kim J-Y (2011) Carbonic anhydrase IX (CA9) modulates tumor-associated cell migration and invasion. J Cell Sci 124:1077-1087
88. Ivanov S, Liao S-Y, Ivanova A, Danilkovitch-Miagkova A, Tarasova N, Weirich G, Merrill MJ, Proescholdt MA, Oldfield EH, Lee J, Zavada J, Waheed A, Sly W, Lerman MI, Stanbridge EJ (2011) Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 158:905-919
89. Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simons JW, Giannakakou P (2003) 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3:363-375
90. Visagie MH, Birkholtz LM, Joubert AM (2014) 17-beta-estradiol analog inhibits cell proliferation by induction of apoptosis in breast cell lines. Microsc Res Tech 77:236-242
91. Rebucci M, Michiels C (2013) Molecular aspects of cancer cell resistance to chemotherapy. Biochem Pharmacol 85:1219-1226
92. Nobili S, Landini I, Mazzei T, Mini E (2012) Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression. Med Res Rev 32:1220-1262
93. Wang F, Zhang D, Zhang Q, Chen Y, Zheng D, Hao L, Duan C, Jia L, Liu G, Liu Y (2011) Synergistic effect of folate-mediated targeting and verapamil-mediated P-gp inhibition with paclitaxel-polymer micelles to overcome multi-drug resistance. Biomaterials 32:9444-9456
94. Baguley BC (2010) Multiple drug resistance mechanisms in cancer. Mol Biotechnol 46:308-316
95. Monzó M, Rosell R, Sánchez JJ, Lee JS, O'Brate A, González-Larriba JL, Alberola V, Lorenzo JC, Núñez L, Ro JY, Martín C (1999) Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol 17:1786
96. Anand S, Penrhyn-Lowe S, Venkitaraman AR (2003) AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 3:51-62
97. Lee C, Dhillon J, Wang M, Gao Y, Hu K, Park E, Hung M-C, Eirew P, Eaves C, Dunn S (2008) Targeting Y-box binding protein-1 (YB-1) in Her-2 over-expressing breast cancer cells induces apoptosis via the signal transducer and activator or transcription-3 (STAT3) pathway and suppresses tumor growth. Clin Cancer Res 14:A14
98. Lee CY-S (2007) Y-box binding protein-1 (YB-1) is essential for the growth and survival of HER-2 over-expressing breast cancer cells. Dissertation, University of British Columbia
99. Rexer BN, Arteaga CL (2012) Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. Crit Rev Oncog 17:1-16
100. Dong X, Xu P, Miao C, Fu Z, Li Q, Tang P, Wang T (2012) Hypoxia decreased chemosensitivity of breast cancer cell line MCF-7 to paclitaxel through cyclin B1. Biomed Pharmacother 66:70-75
101. Kanakkanthara A, Miller JH (2013) MicroRNAs: novel mediators of resistance to microtubule-targeting agents. Cancer Treat Rev 39:161-170
102. Zhou M, Liu Z, Zhao Y, Ding Y, Liu H, Xi Y, Xiong W, Li G, Lu J, Fodstad O, Riker AI, Tan M (2010) MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of proapoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem 285:21496-21507
103. Skipper HE (1971) Kinetics of mammary tumor cell growth and implications for therapy. Cancer 28:1479-1499
104. Kamb A (2005) What's wrong with our cancer models? Nat Rev Drug Discov 4:161-165
105. Meyer CJ, Krauth M, Wick MJ, Shay JW, Gellert G, De Brabander JK, Miller JH (2015) Peloruside A inhibits growth of human lung and breast tumor xenografts in an athymic nu/nu mouse model. Mol Cancer Ther 14:1816-1823
106. Liu JK, Towle MJ, Cheng HS, Saxton P, Reardon C, Wu JY, Littlefield BA (2007) In vitro and in vivo anticancer activities of synthetic (-)-laulimalide, a marine natural product microtubule stabilizing agent. Anticancer Res 27:1509-1518
107. Wolmarans E, Mqoco T, Stander A, Nkandeu S, Sippel K, McKenna R, Joubert A (2014) Novel estradiol analogue induces apoptosis and autophagy in esophageal carcinoma cells. Cell Mol Biol Lett 19:98-115